Blood in the Streets: Why I'm Buying Gold Miners, a Peru Tailings Giant, and Two Biotech 10-Baggers This Summer
Contributed Opinion
Wet AMD Drug Secures First FDA-Approved Bevacizumab Status
FDA Approves First Ophthalmic Treatment for Wet AMD, Leading Wainwright to Triple Price Target
Smith & Nephew Expands Wound Care Portfolio in $22B Market
Melanoma Biotech Secures Nasdaq Listing via All-Share Merger
Biotech's Non-Cytotoxic Copper-Iodine Wound Platform Shows 72-Hour Antimicrobial Persistence in Lab Testing
Scancell, Neuphoria Agree to All-Share Merger
Novocure Hits Record Revenue and Raises 2026 Outlook
Novocure posts record Q2 revenue of $183.6 million and lifts full-year guidance after Optune Pax earns CE Mark approval in Europe. See the key catalysts for investors.Novocure Posts Record Q2 Revenue of US$183.6M
Novocure Ltd. (NVCR:NASDAQ) posted record Q2 2026 revenue of US$183.6 million, up 16% year-over-year, and raised full-year guidance to US$710-US$725 million.US-Listed Rare Disease Biotech Hit With Full Clinical Hold; Data Unblinding Ahead
Research Report
A full FDA clinical hold covers all studies of this hyperphagia candidate, and the company plans to unblind Phase 3 data. An analyst warned the trial "may need to be repeated in its entirety." 
Streetwise Key Charts
